PLSE · CIK 0001625101
What Pulse Biosciences, Inc. told the SEC could break it.
Pulse Biosciences flags the profile of an early-stage medical-device company still proving itself: it has generated only limited product revenue and posted operating losses every year since inception, funding itself with equity and debt such as a 2024 $60M rights offering. Its future leans heavily on FDA decisions — growth depends on approval of clinical candidates like its nPulse Cardiac Clamp and Catheter for atrial fibrillation, with no assurance of success — while trade tariffs and FDA changes could raise costs. Adding a governance wrinkle, about 72% of shares sit with its Co-Chairman and affiliates, concentrating control and thinning stock liquidity.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- trade tariffs and FDA changes raising operating costsmedium
Pulse flags that trade tariffs and changes at the U.S. FDA may adversely affect its operating costs, adding policy uncertainty for a company still scaling commercialization.
“Trade tariffs and changes at the U.S. FDA may adversely affect our operating costs”
- FDA regulatory-approval dependence for AF product candidates (cardiac clamp/catheter)low
Pulse's growth depends on FDA approval of clinical candidates — including its nPulse Cardiac Clamp and Cardiac Catheter for atrial fibrillation (cardiac clamp requires a PMA with pivotal data) — with no assurance of approval or favorable study results.
“We can provide no assurance that our clinical product candidates, including our product candidates for the treatment of atrial fibrillation ("AF"), such as our nPulse Cardiac Clamp and our nPulse Cardiac Catheter, will obtain regulatory approval or that the results of clinical studies will be favorable.”
SEC filing →As of 2026
Liquidity & debt
- limited revenue and significant recurring operating lossesmedium
Pulse Biosciences has generated only limited product revenue and incurred significant operating losses every year since inception, funding itself through equity and debt (e.g., the 2024 $60M Rights Offering), with continued losses expected.
“To date, we have generated only limited revenue from product sales and we have incurred significant operating losses each year since our inception.”
SEC filing →As of 2026
Other disclosures
- controlling-shareholder concentration (Co-Chairman owns ~72%)medium
About 72% of Pulse's outstanding shares are held by its Co-Chairman (Robert Duggan) and affiliates, reducing stock liquidity and giving him control over major decisions and minority-shareholder outcomes.
“Approximately 72% of our outstanding shares are owned by our Co-Chairman and his affiliates, which reduces liquidity of our stock.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch